Education
About Us
Working with TipRanks
Follow Us
ALK-abello A/S Class B (GB:0OIR)
LSE:0OIR
0OIR Stock Chart & Stats
Day’s Range― - ―
52-Week Rangekr131.30 - kr211.80
Previous CloseN/A
Volume3.42K
Average Volume (3M)40.01K
Market Cap
$47.15B
Enterprise Valuekr41.49B
Total Cash (Recent Filing)$316.00M
Total Debt (Recent Filing)$990.00M
Price to Earnings (P/E)46.6
Beta0.93
Next Earnings
Nov 13, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.20
Shares Outstanding202,567,200
10 Day Avg. Volume77,855
30 Day Avg. Volume40,007
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.88
Enterprise Value/Revenue7.27
Enterprise Value/Gross Profit11.28
Enterprise Value/Ebitda26.74
Forecast
1Y Price Target
$184.99Price Target Upside-11.99% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering0
ALK-abello News
0OIR FAQ
What was ALK-abello A/S Class B’s price range in the past 12 months?
ALK-abello A/S Class B lowest share price was kr131.30 and its highest was kr211.80 in the past 12 months.
What is ALK-abello A/S Class B’s market cap?
ALK-abello A/S Class B’s market cap is $47.15B.
When is ALK-abello A/S Class B’s upcoming earnings report date?
ALK-abello A/S Class B’s upcoming earnings report date is Nov 13, 2025 which is in 52 days.
How were ALK-abello A/S Class B’s earnings last quarter?
ALK-abello A/S Class B released its earnings results on Aug 21, 2025. The company reported kr1.2 earnings per share for the quarter, missing the consensus estimate of kr1.3 by -kr0.1.
Is ALK-abello A/S Class B overvalued?
According to Wall Street analysts ALK-abello A/S Class B’s price is currently Overvalued.
Does ALK-abello A/S Class B pay dividends?
ALK-abello A/S Class B does not currently pay dividends.
What is ALK-abello A/S Class B’s EPS estimate?
ALK-abello A/S Class B’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ALK-abello A/S Class B have?
ALK-abello A/S Class B has 202,567,200 shares outstanding.
What happened to ALK-abello A/S Class B’s price movement after its last earnings report?
ALK-abello A/S Class B reported an EPS of kr1.2 in its last earnings report, missing expectations of kr1.3. Following the earnings report the stock price went up 7.319%.
Which hedge fund is a major shareholder of ALK-abello A/S Class B?
Currently, no hedge funds are holding shares in GB:0OIR
Company Description
ALK-abello A/S Class B
ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. It product portfolio include GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDACURE, and ITULAZAX for treatment of allergic rhinitis and allergic asthma. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including grass, ragweed, house dust mite, Japanese cedar, tree, and food. It also provides consumer healthcare solution, which include Digital eco-system, a platform which connect and engages with allergy sufferers much earlier in the disease journey through tools and e-commerce offerings that supports, guidance and relief, and smoothing the path to allergy immunotherapy treatment. In addition, the company offers diagnostic allergy solutions through testing by skin prick test or blood test; and emergency treatment, such as intramuscular injection of adrenaline for the treatment of acute life-threatening allergic reactions including Anaphylaxis. ALK-Abelló A/S was founded in 1923 and is headquartered in Hørsholm, Denmark.
0OIR Company Deck
0OIR Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue and earnings growth, with successful product launches and an upgraded revenue outlook. However, challenges in China, SCIT sales decline, and supply constraints in Japan were noted as areas of concern.View all GB:0OIR earnings summariesTechnical Analysis
ALK-abello
―
Dynavax
―
Inovio Pharmaceuticals
―
Aclaris Therapeutics
―
Emergent Biosolutions
―
Novartis
―
Bristol-Myers Squibb
―
Options Prices
Currently, No data available
---